Quantcast
Home > Quotes > ZFGN
ZFGN

Zafgen, Inc. Common Stock (ZFGN) Quote & Summary Data

$2.57
*  
0.11
4.47%
Get ZFGN Alerts
*Delayed - data as of May 21, 2019 15:24 ET  -  Find a broker to begin trading ZFGN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ZFGN Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2.57 / $ 2.58
1 Year Target
6
Today's High / Low
$ 2.58 / $ 2.425
Share Volume
79,757
50 Day Avg. Daily Volume
318,061
Previous Close
$ 2.46
52 Week High / Low
$ 12.355 / $ 2.33
Market Cap
95,930,120
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.72
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.83

Intraday Chart

Shares Traded

Share Volume:
79,757
50 Day Avg. Daily Volume:
318,061

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.72

Trading Range

The current last sale of $2.57 is 10.30% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.58 $ 12.355
 Low: $ 2.425 $ 2.33

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company leveraging our proprietary methionine aminopeptidase 2, or MetAP2, biology platform to develop novel therapies for patients affected by complex metabolic diseases. We have pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders and we are currently advancing programs for type 2 diabetes, Prader-Willi syndrome, or PWS, and liver diseases. Our lead product candidate is ZGN-1061, a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is currently being profiled for its utility in the treatment of type 2 diabetes. Type 2 diabetes is a prevalent, chronic, progressive, multifactorial disease that leads to increased microvascular and macrovascular disease, and as such, increases risk of death from cardiovascular disease, stroke, and kidney failure. Type 2 diabetes is also a leading cause of lower-limb amputation and blindness.  ... More ...  



Risk Grade

Where does ZFGN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.45
Open Date:
May 21, 2019
Close Price:
$ 2.46
Close Date:
May 20, 2019


Consensus Recommendation

Analyst Info